Also, for each of the two MRSA antigens, only the c-di-GMP-adjuvanted vaccines induced significant

levels of various specific IgG subtypes. Surprisingly, alum-adjuvanted vaccines did not induce strong, specific anti-SEC or anti-ClfA antibodies in the sera. The potential for the use of c-di-GMP as a vaccine adjuvant was also demonstrated in a mouse model of i.p. pneumococcal infection. In this case, mice were intraperitoneally vaccinated with either S. pneumoniae pneumolysin toxoid (PdB) or pneumococcal surface protein A (PspA) adjuvanted with either c-di-GMP or alum. A predominantly IgG1 response was elicited as determined by antigen-specific antibody responses but again pneumococcal antigen adjuvanted with c-di-GMP resulted in stronger specific antibody response than antigen MK-8776 nmr adjuvanted selleck compound with alum. Furthermore, mice immunized with PdB + c-di-GMP showed a significantly longer median survival time (>504 h) and a better survival rate than control mice vaccinated with c-di-GMP alone (∼60 h). Similar data were observed in mice immunized with PspA + c-di-GMP although in this case the difference failed to reach statistical significance [21]. This may be due to the fact that c-di-GMP alone seemed to have some protective efficacy (4/15 mice immunized with c-di-GMP alone survived). More encouragingly, PdB + c-di-GMP vaccinated mice survived significantly longer than the positive control mice

immunized with PdB + alum vaccine. Interestingly, results from this work also mirrored those from the MRSA challenge study in that antigen adjuvanted with c-di-GMP

elicited higher levels of specific antibodies and better protective immunity than antigen adjuvanted with alum. The above studies have used c-di-GMP as a systemic adjuvant. While the results are quite tuclazepam encouraging, the possibility of using c-di-GMP as a mucosal adjuvant is an even more exciting prospect since human mucosal surfaces (such as respiratory, gastrointestinal (GI) and urogenital tracts) are the major portals of entry and sites of diseases caused by microbial pathogens [30] and [31]. Thus, development of adjuvants/vaccines that elicit effective and sustained mucosal immune responses to prevent the attachment, invasion and replication of the pathogen would be a significant advancement in the prevention and treatment of many socially and economically important infectious diseases. Most of the currently approved human vaccines are administered systemically, and they generally fail to elicit effective mucosal immunity [3], [31] and [32]. Hence, there are ongoing world-wide efforts in developing mucosal adjuvants and vaccine delivery systems [3], [30] and [31]. An effective mucosal vaccine must reach and breach the epithelial barrier. However, the mucosal epithelium is composed of a thin layer of cells sealed at their apical membranes by tight junctions, which is further protected by mucus and secretory IgA.